A Novo spokesperson said the Danish drugmaker was not ruling out further legal action after announcing new lawsuits against ...

号称千亿美元规模的减肥药市场已然是一片红海，而各大主流减肥药的产品效果都有何区别？从双雄争霸到百花齐放，减肥药市场上新增了哪些玩家？面临合作翻车、专利即将到期等多重夹击的诺和诺德临场换帅，但资本会认可这位新CEO吗？

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

据悉，司美格鲁肽在加拿大受到两重专利保护。首先是数据独占权，加拿大规定药物获批后8年内禁止任何人尝试仿制。这一保护自2018年生效，并于2026年1月到期；另一项则是诺和诺德主动不再维持的专利，这项保护本应在2026年3月到期，但实际上已经于2020 ...

Investing.com -- 随着诺和诺德公司 (NYSE: NVO )宣布对生产和销售复合司美格鲁肽产品的公司提起14项新诉讼，Hims & Hers Health (NYSE: HIMS )股价周二小幅下跌，延续了其因业绩不佳而导致的10%跌幅。

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

STORY: Novo Nordisk is ramping up lawsuits against U.S. companies selling cheaper versions of its weight-loss drug Wegovy. But one firm remains conspicuously absent: Hims & Hers.This telehealth ...

Hims & Hers Health stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...